Elevation Oncology Inc (NASDAQ:ELEV) price on Friday, May 02, rose 2.91% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.35.
A look at the stock’s price movement, the close in the last trading session was $0.34, moving within a range at $0.3387 and $0.3556. The beta value (5-Year monthly) was 1.668. Turning to its 52-week performance, $4.33 and $0.22 were the 52-week high and 52-week low respectively. Overall, ELEV moved 33.59% over the past month.
Elevation Oncology Inc’s market cap currently stands at around $20.73 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-05.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ELEV is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend ELEV as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ELEV’s current price about 7.63% and -9.21% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 49.67, while 7-day volatility ratio is 9.76% and 10.65% in the 30-day chart. Further, Elevation Oncology Inc (ELEV) has a beta value of 1.61, and an average true range (ATR) of 0.04. Analysts have given the company’s stock an average 52-week price target of $9, forecast between a low of $8 and high of $10. Looking at the price targets, the low is -2185.71% off current price level while to achieve the yearly target high, price needs to move -2757.14%. Nonetheless, investors will most likely welcome a -2471.43% jump to $9 which is the analysts’ median price.
If we refocus on Elevation Oncology Inc (NASDAQ:ELEV), historical trading data shows that trading volumes averaged 0.83 over the past 10 days and 1.48 million over the past 3 months. The company’s latest data on shares outstanding shows there are 59.13 million shares.
The 12.09% of Elevation Oncology Inc’s shares are in the hands of company insiders while institutional holders own 66.15% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.63 million on 2025-04-15, giving us a short ratio of 4.01. The data shows that as of 2025-04-15 short interest in Elevation Oncology Inc (ELEV) stood at 1540.0 of shares outstanding, with shares short falling to 8.75 million registered in 2025-03-14. Current price change has pushed the stock -37.79% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ELEV stock continues to rise going into the next quarter.
